AUTHOR=Schamroth Pravda Nili , Mishaev Raffael , Levi Amos , Witberg Guy , Shapira Yaron , Orvin Katia , Barkan Yeela Talmor , Hamdan Ashraf , Sharoni Ram , Perl Leor , Sagie Alexander , Assa Hana Vaknin , Kornowski Ran , Codner Pablo TITLE=Five-Year Outcomes of Patients With Mitral Structural Valve Deterioration Treated With Transcatheter Valve in Valve Implantation – A Single Center Prospective Registry JOURNAL=Frontiers in Cardiovascular Medicine VOLUME=9 YEAR=2022 URL=https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.883242 DOI=10.3389/fcvm.2022.883242 ISSN=2297-055X ABSTRACT=
The Valve-in-Valve (ViV) technique is an emerging alternative for the treatment of bioprosthetic structural valve deterioration (SVD) in the mitral position. We report on intermediate-term outcomes of patients with symptomatic SVD in the mitral position who were treated by transcatheter mitral valve-in-valve (TM-ViV) implantation during the years 2010–2019 in our center. Three main outcomes were examined during the follow-up period: NYHA functional class, TM-ViV hemodynamic data per echocardiography, and mortality. Our cohort consisted of 49 patients (mean age 77.4 ± 10.5 years, 65.3% female). The indications for TM-ViV were mainly for regurgitant pathology (77.6%). All 49 patients were treated with a balloon-expandable device. The procedure was performed